1-(3-hydroxyphenyl)-1-hexanol | 92532-21-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(3-hydroxyphenyl)-1-hexanol
• 英文别名: 3-(1-hydroxyhexyl)phenol；1-(3-hydroxy-phenyl)-hexan-1-ol；(+/-)-3-Hydroxy-1-(1-hydroxy-hexyl)-benzol；(+/-)-3-(1-Hydroxy-hexyl)-phenol；3-(α-hydroxyhexyl)phenol；3-(1-hydroxyhexyl)-phenol
• CAS: 92532-21-3
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: IBFOMXXVRQYPGR-UHFFFAOYSA-N

物化性质

• 熔点：
  100-100.5 °C
• 沸点：
  338.1±17.0 °C(Predicted)
• 密度：
  1.050±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-hydroxyphenyl)-1-hexanol 在 乙醇 、 copper oxide-chromium oxide 、 甲烷 作用下， 185.0 ℃ 、11.77 MPa 条件下， 生成 3-Hexyl-phenol
  参考文献：
  名称：

  Syntheses Leading to Substituted Tetrahydrofluorenols

  摘要：

  DOI：

  10.1021/ja01238a008
• 作为产物：
  描述：

  trans-3-(3-hex-2-enoyl)phenol 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、101.32 kPa 条件下， 反应 1.0h， 以98%的产率得到1-(3-hydroxyphenyl)-1-hexanol
  参考文献：
  名称：

  Synthesis and conformation of 2-[[3-(1-hydroxyhexyl)phenoxy]methyl]quinoline, a 5-lipoxygenase inhibitor and leukotriene antagonist

  摘要：

  DOI：

  10.1021/jo00064a043

文献信息

• Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists
  作者：John H. Musser、Utpal R. Chakraborty、Stanley Sciortino、Robert J. Gordon、Atul Khandwala、Edward S. Neiss、Thaddeus P. Pruss、Richard Van Inwegen、Ira Weinryb、Stephen M. Coutts

  DOI：10.1021/jm00384a017

  日期：1987.1

  compound, 2-[[3-(1-hydroxyhexyl)phenoxy]-methyl]quinoline (33), had an I50 of 0.12 microM in the rat PMN 5-LO assay and an I50 of 3.6 microM in the leukotriene-induced contraction of GP lung parenchymal strips, and it also showed 91% inhibition of SRS-A-mediated bronchospasm in the GP in vivo at 10 mg/kg, administered intraduodenally. Some of the compounds in this series were also leukotriene antagonists

  已经制备了一系列新的取代的芳基甲基苯基醚。这些化合物已被测试为大鼠中性粒细胞中的5-脂氧合酶（5-LO）抑制剂，白三烯诱导的豚鼠肺实质条带收缩的体外拮抗剂以及过敏反应的慢反应物质抑制剂（SRS-A） GP体内介导的支气管痉挛。这类潜在的抗过敏/抗炎剂的大多数代表在大鼠PMN中显示出对5-LO活性的有效抑制作用。最有效的化合物2-[[[3-（1-（羟基己基）苯氧基]-甲基]喹啉（33）在大鼠PMN 5-LO分析中的I50为0.12 microM，在白三烯-中的I50为3.6 microM。诱导GP肺实质条带收缩，并且在10 mg / kg的体内GP中还表现出91％的SRS-A介导的支气管痉挛抑制，十二指肠内给药。该系列中的某些化合物在体外也是白三烯拮抗剂，其中一些在GP中显示出针对SRS-A介导的支气管痉挛的体内活性。
• Certain unsymmetrical quinolinyl ethers having anti-inflammatory and
  申请人：USV Pharmaceutical Corporation

  公开号：US04794188A1

  公开（公告）日：1988-12-27

  Compounds of the formula: Ar.sub.1 -X-Ar-Z-(R).sub.n' and salts thereof, wherein Ar.sub.1 is a nitrogen, sulfur or oxygen heterocyclic ring; Ar is a phenyl ring or a nitrogen, oxygen or sulfur heterocyclic ring; Ar and Ar.sub.1 may be fully substituted or less than fully substituted with H, CH.sub.3, lower alkyl, aryl, aralkyl, halo, hydroxy, lower alkoxy, CF.sub.3, carboxy, alkylcarboxy, arylcarboxy, alkylcarbalkoxy, alkanoyl, formyl, oxo, nitrilo, amino, aminoalkyl, alkylamine, carboxamide, aryloxy, nitro, sulfonyl, sulfonamide, thio, alkylthio, hydroxyalkyl or oxyalkylcarbalkoxy; X= ##STR1## of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms, ##STR2## Z is an alkylene chain containing up to 10 carbon atoms in the principal chain and a total of up to 12 carbon atoms and from 0 to 2 double bonds and the said alkylene chain may be attached to Ar through an oxygen, sulfur or amino nitrogen atom, and when n'=2, one of the R substituents may be halogen on an omega carbon of the alkylene chain Z; when n'=1, R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of .dbd.O, OR.sub.3, SR.sub.3, N(R.sub.2).sub.2 and R.sub.1, --COR.sub.4 and when n'=2 one R is previously defined and the additional R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of .dbd.O, OR.sub.3, SR.sub.3, N(R.sub.2).sub.2, --COR.sub.4, lactone and halo; R.sub.1 is H or CH.sub.3 ; R.sub.2 is H, lower alkyl, aryl or aralkyl; R.sub.3 is H, lower alkyl, lower alkanoyl, aryl, aralkyl or substituted aryl in which the substituent is halo, lower alkyl or lower alkoxy; R.sub.4 is OR.sub.2 or N(R.sub.2).sub.2 ; n=0 or 1; n'=1 to 7; and n"=0, 1 or 2.

  该公式的化合物是：Ar.sub.1 -X-Ar-Z-(R).sub.n'及其盐，其中Ar.sub.1是氮、硫或氧杂环；Ar是苯环或氮、氧或硫杂环；Ar和Ar.sub.1可能完全或部分取代为H、CH.sub.3、较低烷基、芳基、芳基烷基、卤素、羟基、较低烷氧基、CF.sub.3、羧基、烷基羧基、芳基羧基、烷基羧烷氧基、烷酰基、酰基、氧代、亚硝基、氨基、氨基烷基、烷基胺、羧酰胺、芳氧基、硝基、磺酰基、磺酰胺、硫、烷硫、羟基烷基或氧基烷氧基羧烷；X= ##STR1## 主链中最多含有2个碳原子，并且总共最多含有4个碳原子，##STR2## Z是主链中含有最多10个碳原子和总共最多12个碳原子以及0到2个双键的烷基链，该烷基链可以通过氧、硫或氨基氮原子连接到Ar上，当n'=2时，Z的烷基链上的一个R取代基可能是Z的ω碳上的卤素；当n'=1时，R是连接到Z的碳原子中的一个的取代基，选择自.dbd.O、OR.sub.3、SR.sub.3、N(R.sub.2).sub.2和R.sub.1的群，--COR.sub.4，当n'=2时，一个R已经定义，额外的R是连接到Z的碳原子中的一个的取代基，选择自.dbd.O、OR.sub.3、SR.sub.3、N(R.sub.2).sub.2、--COR.sub.4、内酯和卤素的群；R.sub.1是H或CH.sub.3；R.sub.2是H、较低烷基、芳基或芳基烷基；R.sub.3是H、较低烷基、较低烷酰基、芳基、芳基烷基或取代芳基，其中取代基是卤素、较低烷基或较低烷氧基；R.sub.4是OR.sub.2或N(R.sub.2).sub.2；n=0或1；n'=1到7；n"=0、1或2。
• Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or
  申请人：USV Pharmaceutical Corporation

  公开号：US04567184A1

  公开（公告）日：1986-01-28

  Compounds of the structure ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.1 and R.sub.2 are independently hydrogen, alkyl, carboxy, alkylcarboxy, arylcarboxy, alkyl carbalkoxy, alkanoyl, formyl, nitrile, amino, amino alkyl, alkylamine, carboxamide, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, nitro, sulfonyl, sulfonamide, thio, alkylthio, or R.sub.1 and R.sub.2 can be taken together to form a phenyl ring; B is C or N, in which N can be in any position of the ring; X is O, S, NR.sub.4, CH.sub.2 Z, CH.dbd.N, CH.dbd.CH, C.tbd.C, CH.sub.2 ZCH.sub.2, C.dbd.O, C.dbd.CR or WC.dbd.O; Y is CHCH.sub.2, C.dbd.CH, C--CH.sub.2, CHCHR.sub.5, CHC(R.sub.5).sub.2 or CC(R.sub.5).sub.2 ; R.sub.3 is O, OH, OR.sub.4, SH, SR.sub.4, NH, HNR.sub.4 or N(R.sub.4).sub.2 ; and M is an integer from 0 to 10; wherein Z is O, S or NR.sub.4 ; R.sub.4 is H, alkyl or aryl; W is O, S or NR.sub.4 ; and R.sub.5 is H, alkyl or fluoro have antiinflammatory and antiallergic activities.

  结构式为##STR1##的化合物及其药学上可接受的盐，其中R.sub.1和R.sub.2独立地为氢、烷基、羧基、烷基羧基、芳基羧基、烷基卡巴酯、烷酰基、甲酰基、腈基、氨基、氨基烷基、烷基胺、羧酰胺、卤素、三卤甲基、羟基、烷氧基、芳氧基、硝基、磺酰基、磺酰胺、硫、烷硫基，或R.sub.1和R.sub.2可以共同形成苯环；B为C或N，其中N可以在环的任何位置；X为O、S、NR.sub.4、CH.sub.2 Z、CH.dbd.N、CH.dbd.CH、C.tbd.C、CH.sub.2 ZCH.sub.2、C.dbd.O、C.dbd.CR或WC.dbd.O；Y为CHCH.sub.2、C.dbd.CH、C--CH.sub.2、CHCHR.sub.5、CHC(R.sub.5).sub.2或CC(R.sub.5).sub.2；R.sub.3为O、OH、OR.sub.4、SH、SR.sub.4、NH、HNR.sub.4或N(R.sub.4).sub.2；M为0到10的整数；其中Z为O、S或NR.sub.4；R.sub.4为H、烷基或芳基；W为O、S或NR.sub.4；R.sub.5为H、烷基或氟，具有抗炎和抗过敏活性。
• Certain [3-(1-hydroxy hexyl-tetrahydro)naphthalenes], the corresponding
  申请人：USV Pharmaceutical Corporation

  公开号：US04778931A1

  公开（公告）日：1988-10-18

  The invention relates to several aryloxy-alkane alcohols, for example 1-(3-(1-hydroxy-1-methylhexyl) phenoxy methyl)-2-methoxy-naphthalene, 2-(1-(3-(1-hydroxy-2,2-dimethylhexyl)phenoxy)ethyl naphthalene, 1-(3-6-phenoxy-1-hydroxyhexyl)phenoxy methyl)-4-methoxy naphthalene, 2-(3-(1-hydroxyhexyl) phenoxymethyl) naphthalene and 2-(3-(1-hydroxyhexyl)phenoxymethyl)-1,2,3,4-tetrahydro naphthalene, methods for their preparation and their use for treating inflammatory and allergic conditions in a mammal.

  该发明涉及几种芳氧基-烷基醇，例如1-(3-(1-羟基-1-甲基己基)苯氧甲基)-2-甲氧基萘，2-(1-(3-(1-羟基-2,2-二甲基己基)苯氧)乙基萘，1-(3-6-苯氧基-1-羟基己基)苯氧甲基)-4-甲氧基萘，2-(3-(1-羟基己基)苯氧甲基)萘和2-(3-(1-羟基己基)苯氧甲基)-1,2,3,4-四氢萘，以及它们的制备方法和用于治疗哺乳动物的炎症和过敏症状的用途。
• Hydroxamic acids and pharmaceutical compositions containing them, and
  申请人：Boehringer Mannheim GmbH

  公开号：US04906666A1

  公开（公告）日：1990-03-06

  The present invention provides compounds of the general formula: ##STR1## wherein Ar is a phenyl radical optionally substituted by alkyl, alkenyl, alkoxy, alkylthio, alkanoyl, hydroxyl, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, nitro, amino or halogen, A is a straight-chained or branched, saturated or unsaturated C.sub.1 -C.sub.8 aliphatic hydrocarbon radical which is optionally substituted by a hydroxyl group, n is 0, 1 or 2, B is a straight-chained or branched, saturated or unsaturated C.sub.1 -C.sub.8 -aliphatic hydrocarbon radical and R is 5-(1H)-tetrazolyl, --CO--NH-tetrazolyl, ##STR2## CN, SCN, OH, halogen, 5-(1H)-tetrazolylthio, ##STR3## or CO--O--NH--R.sub.1, wherein R.sub.1 is a hydrogen atom, an alkyl radical optionally substituted by cycloalkyl or an alkenyl, cycloalkyl, aralkyl or aryl radical, wherein the aromatic moiety can be substituted by alkyl, alkenyl, alkoxy, alkylthio, alkanoyl, hydroxyl, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, nitro, amino or halogen; and the pharmacologically acceptable salts thereof. The present invention also provides processes for preparing these compounds and pharmaceutical compositions containing them for combating allergic diseases.

  本发明提供了一般式为：##STR1##的化合物，其中Ar是苯基基团，可选择地被烷基，烯基，烷氧基，烷硫基，烷酰基，羟基，羟基烷基，羧基，烷氧羰基，氨基甲酰基，硝基，氨基或卤素取代；A是直链或支链，饱和或不饱和的C.sub.1-C.sub.8脂肪烃基团，可选择地被羟基基团取代，n为0、1或2，B是直链或支链，饱和或不饱和的C.sub.1-C.sub.8脂肪烃基团，R为5-(1H)-四唑基，--CO--NH-四唑基，##STR2## CN，SCN，OH，卤素，5-(1H)-四唑基硫，##STR3##或CO--O--NH--R.sub.1，其中R.sub.1是氢原子，烷基基团，可选择地被环烷基取代或烯基，环烷基，芳基烷基或芳基基团，其中芳香基团可选择地被烷基，烯基，烷氧基，烷硫基，烷酰基，羟基，羟基烷基，羧基，烷氧羰基，氨基甲酰基，硝基，氨基或卤素取代；以及其药学上可接受的盐。本发明还提供制备这些化合物的方法和包含它们的药物组合物，用于治疗过敏性疾病。